Hemolytic-uremic syndrome classification

Jump to navigation Jump to search

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome classification

CDC on Hemolytic-uremic syndrome classification

Hemolytic-uremic syndrome classification in the news

Blogs on Hemolytic-uremic syndrome classification

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

HUS may be classified according etiology into 4 subtypes including diarrhoea-associated HUS, non-diarrhea-associated HUS (D−HUS), Streptococcus pneumoniae‐associated HUS, diacylglycerol kinase‐ε (DGKE)‐associated HUS.

Classification

Hemolytic-Uremic syndrome (HUS) may be classified as follows:

Typical Or Diarrhea Related

  • Shiga-Toxin producing E.Coli/ Shigella infection

Atypical or Non Diarrheal

Primary Causes

  • Complement Factor abnormalities
    • Complement factor H (CFH) mutation/ Factor H Defeciency (Autosomal Dominant)
    • Complement Factor I(CFI) Defeciency (Acquired antibody mediated)
    • Membrane co-factor protein Defeciency (MCP; CD46)[1]
    • Factor B Overactivity (Complement Factor B mutation)[2]

References

  1. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH; et al. (2008). "Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome". Blood. 111 (2): 624–32. doi:10.1182/blood-2007-04-084533. PMC 2200836. PMID 17914026.
  2. Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A; et al. (2014). "Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?". J Am Soc Nephrol. 25 (9): 2053–65. doi:10.1681/ASN.2013070796. PMC 4147975. PMID 24652797.

Template:WH Template:WS